WO1995021151A1 - Process for the hydrogenation of imines - Google Patents

Process for the hydrogenation of imines Download PDF

Info

Publication number
WO1995021151A1
WO1995021151A1 PCT/EP1995/000221 EP9500221W WO9521151A1 WO 1995021151 A1 WO1995021151 A1 WO 1995021151A1 EP 9500221 W EP9500221 W EP 9500221W WO 9521151 A1 WO9521151 A1 WO 9521151A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
process according
phenyl
acid
phosphine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1995/000221
Other languages
English (en)
French (fr)
Inventor
Hans-Peter Jalett
Felix Spindler
Hans-Ulrich Blaser
Reinhard Georg Hanreich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Priority to JP52034895A priority Critical patent/JP3833699B2/ja
Priority to EP95906339A priority patent/EP0691949B1/en
Priority to CA002157191A priority patent/CA2157191C/en
Priority to SK1366-95A priority patent/SK281759B6/sk
Priority to HU9502851A priority patent/HU219731B/hu
Priority to KR1019950704200A priority patent/KR100355255B1/ko
Priority to DE69505312T priority patent/DE69505312T2/de
Priority to PL95310965A priority patent/PL179441B1/pl
Priority to AU14566/95A priority patent/AU677753B2/en
Priority to BR9505836A priority patent/BR9505836A/pt
Priority to DK95906339T priority patent/DK0691949T3/da
Publication of WO1995021151A1 publication Critical patent/WO1995021151A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22Organic complexes
    • B01J31/2282Unsaturated compounds used as ligands
    • B01J31/2291Olefins
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22Organic complexes
    • B01J31/2282Unsaturated compounds used as ligands
    • B01J31/2295Cyclic compounds, e.g. cyclopentadienyls
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2409Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2442Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems
    • B01J31/2447Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as substituents on a ring of the condensed system or on a further attached ring
    • B01J31/2452Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as substituents on a ring of the condensed system or on a further attached ring with more than one complexing phosphine-P atom
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2442Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems
    • B01J31/2447Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as substituents on a ring of the condensed system or on a further attached ring
    • B01J31/2452Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as substituents on a ring of the condensed system or on a further attached ring with more than one complexing phosphine-P atom
    • B01J31/2457Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as substituents on a ring of the condensed system or on a further attached ring with more than one complexing phosphine-P atom comprising aliphatic or saturated rings, e.g. Xantphos
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2442Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems
    • B01J31/2461Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as ring members in the condensed ring system or in a further ring
    • B01J31/2471Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as ring members in the condensed ring system or in a further ring with more than one complexing phosphine-P atom
    • B01J31/2476Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as ring members in the condensed ring system or in a further ring with more than one complexing phosphine-P atom comprising aliphatic or saturated rings
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2442Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems
    • B01J31/2461Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as ring members in the condensed ring system or in a further ring
    • B01J31/248Bridged ring systems, e.g. 9-phosphabicyclononane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/24Preparation of compounds containing amino groups bound to a carbon skeleton by reductive alkylation of ammonia, amines or compounds having groups reducible to amino groups, with carbonyl compounds
    • C07C209/26Preparation of compounds containing amino groups bound to a carbon skeleton by reductive alkylation of ammonia, amines or compounds having groups reducible to amino groups, with carbonyl compounds by reduction with hydrogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/44Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers
    • C07C209/52Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers by reduction of imines or imino-ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/36Nitrogen atoms
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/60Reduction reactions, e.g. hydrogenation
    • B01J2231/64Reductions in general of organic substrates, e.g. hydride reductions or hydrogenations
    • B01J2231/641Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes
    • B01J2231/643Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes of R2C=O or R2C=NR (R= C, H)
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/02Compositional aspects of complexes used, e.g. polynuclearity
    • B01J2531/0202Polynuclearity
    • B01J2531/0205Bi- or polynuclear complexes, i.e. comprising two or more metal coordination centres, without metal-metal bonds, e.g. Cp(Lx)Zr-imidazole-Zr(Lx)Cp
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/02Compositional aspects of complexes used, e.g. polynuclearity
    • B01J2531/0261Complexes comprising ligands with non-tetrahedral chirality
    • B01J2531/0266Axially chiral or atropisomeric ligands, e.g. bulky biaryls such as donor-substituted binaphthalenes, e.g. "BINAP" or "BINOL"
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82Metals of the platinum group
    • B01J2531/827Iridium
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80Complexes comprising metals of Group VIII as the central metal
    • B01J2531/84Metals of the iron group
    • B01J2531/842Iron
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/04Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing carboxylic acids or their salts
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/26Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups B01J31/02 - B01J31/24

Definitions

  • the present invention relates to a process for the hydrogenation of imines with hydrogen under elevated pressure in the presence of iridium catalysts and a halide, wherein the reaction mixture contains an inorganic or organic acid.
  • US-A-4994615 describes a process for the asymmetric hydrogenation of prochiral N-arylketimines wherein iridium catalysts having chiral diphosphine ligands are used.
  • US-A-5 011 995 describes a process for the asymmetric hydrogenation of prochiral N-alkylketimines using the same catalysts.
  • US-A-5 112999 discloses polynuclear iridium compounds and a complex salt of iridium, which contain diphosphine ligands, as catalysts for the hydrogenation of imines.
  • the catalyst activity can be increased by a factor of 10 or more if the reaction mixture essentially contains a halide and also contains an acid. It has also unexpectedly been found that at the same time the deactivation of the catalysts can be considerably reduced or completely eliminated. It has also been found, surprisingly, that the enantioselectivity under the chosen conditions is high, and high optical yields of, for example, up to 80 % can be achieved, even at reaction temperatures of more than 50°C.
  • the invention relates to a process for the hydrogenation of imines with hydrogen under elevated pressure in the presence of iridium catalysts and with or without an inert solvent, wherein the reaction mixture contains an ammonium chloride, bromide or iodide, or a metal chloride, bromide or iodide that is soluble in the reaction mixture, the metal preferably being an alkali metal, and additionally contains an acid.
  • Suitable imines are especially those that contain at least one group.
  • the groups are substituted asymmetrically and are thus compounds having a prochiral ketimine group, it is possible in the process according to the invention for mixtures of optical isomers or pure optical isomers to be formed if enantioselective or diastereoselective iridium catalysts are used.
  • the imines may contain further chiral carbon atoms.
  • the free bonds in the above formulae may be saturated with hydrogen or organic radicals having from 1 to 22 carbon atoms or organic hetero radicals having from 1 to 20 carbon atoms and at least one hetero atom from the group O, S, N and P.
  • the nitrogen atom of the group may also be saturated with NH 2 or a primary amino group having from 1 to 22 carbon atoms or a secondary amino group having from 2 to 40 carbon atoms.
  • the organic radicals may be substituted, for example, by F, Cl, Br, C 1 -C 4 haloalkyl wherein halogen is preferably F or Cl, -CN, -NO 2 , -CO 2 H, -CONH 2 , -SO 3 H, -PO 3 H 2 , or C 1 -C 12 alkyl esters or amides, or by phenyl esters or benzyl esters of the groups -CO 2 H, -SO 3 H and -PO 3 H 2 .
  • Aldimine and ketimine groups are especially reactive, with the result that using the process according to the invention it is possible selectively to hydrogenate groups in addition to the and/or groups. Aldimine and
  • ketimine groups are also to be understood to include hydrazone groups.
  • the process according to the invention is suitable especially for the hydrogenation of aldimines, ketimines and hydrazones with the formation of corresponding amines and hydrazines, respectively.
  • the ketimines are preferably N-substituted. It is preferable to use chiral iridium catalysts and to hydrogenate enantiomerically pure, chiral or prochiral ketimines to prepare optical isomers, the optical yields (enantiomeric excess, ee) being, for example, higher than 30 %, preferably higher than 50 %, and yields of more than 90 % being achievable.
  • the optical yield indicates the ratio of the two stereoisomers formed, which ratio may be, for example, greater than 2:1 and preferably greater than 4:1.
  • the imines are preferably imines of formula I
  • R 3 is preferably a substituent and wherein
  • R 3 is linear or branched C 1 -C 12 alkyl, cycloalkyl having from 3 to 8 ring carbon atoms; heterocycloalkyl bonded via a carbon atom and having from 3 to 8 ring atoms and 1 or 2 hetero atoms from the group O, S and NR 6 ; a C 7 -C 16 aralkyl bonded via an alkyl carbon atom or C 1 -C 12 alkyl substituted by the mentioned cycloalkyl or heterocycloalkyl or heteroaryl;
  • R 3 is C 6 -C 12 aryl, or C 1 -C 11 heteroaryl bonded via a ring carbon atom and having 1 or 2 hetero atoms in the ring; R 3 being unsubstituted or substituted by -CN, -NO 2 , F, Cl, C 1 -C 12 alkyl, C 1 -C 12 alkoxy, C 1 -C 12 alkylthio, C 1 -C 6 haloalkyl, -OH, C 6 -C 12 -aryl or
  • R 4 and R 5 are each independently of the other hydrogen, C 1 -C 12 alkyl, phenyl or benzyl, or
  • R 4 and R 5 together are terra- or penta-methylene or 3-oxapentylene;
  • R 6 has independently the same meaning as given for R 4 ;
  • R 1 and R 2 are each independently of the other a hydrogen atom, C 1 -C 12 alkyl or cycloalkyl having from 3 to 8 ring carbon atoms, each of which is unsubstituted or substituted by
  • the radicals R 1 , R 2 and R 3 may contain one or more chirality centres.
  • R 1 , R 2 and R 3 can be substituted in any desired positions by identical or different radicals, for example by from 1 to 5, preferably from 1 to 3, substituents.
  • Suitable substituents for R 1 and R 2 and R 3 are: C 1 -C 12 -, preferably C 1 -C 6 -, and especially C 1 -C 4 -alkyl, -alkoxy or -alkylthio, e.g. methyl, ethyl, propyl, n-, iso- and tert-butyl, the isomers of pentyl, hexyl, octyl, nonyl, decyl, undecyl and dodecyl, and corresponding alkoxy and alkylthio radicals;
  • aryl is preferably naphthyl and especially phenyl, C 7 -C 16 -aralkyl, -aralkoxy and -aralkylthio, in which the aryl radical is preferably naphthyl and especially phenyl and the alkylene radical is linear or branched and contains from 1 to 10, preferably from 1 to 6 and especially from 1 to 3, carbon atoms, for example benzyl, naphthyhnethyl, 1- or 2-phenyl-eth-1-yl or -eth-2-yl, 1-, 2- or 3-phenyl-prop-1-yl, -prop-2-yl or -prop-3-yl, with benzyl being especially preferred;
  • the radicals containing the aryl groups mentioned above may in turn be mono- or polysubstituted, for example by C 1 -C 4 -alkyl, -alkoxy or -alkylthio, halogen, -OH, -CONR 4 R 5 or by -COOR 5 , wherein R 4 and R 5 are as defined; examples are methyl, ethyl, n- and isopropyl, butyl, corresponding alkoxy and alkylthio radicals, F, Cl, Br, dimethyl-, methylethyl- and diethyl-carbamoyl and methoxy-, ethoxy-, phenoxy- and benzyloxy-carbonyl; halogen, preferably F and Cl; secondary amino having from 2 to 24, preferably from 2 to 12 and especially from 2 to 6 carbon atoms, the secondary amino preferably containing 2 alkyl groups, for example dimethyl-, methylethyl-, diethyl-, methyl
  • R 4 and R 5 are each independently of the other C 1 -C 12 -, preferably C 1 -C 6 -, and especially C 1 -C 4 -alkyl, or R 4 and R 5 together are tetra- or penta-methylene or 3-oxapentylene, the alkyl being linear or branched, e.g.
  • R 4 is C 1 -C 12 -, preferably C 1 -C 6 -alkyl, which may be linear or branched, e.g. methyl, ethyl, n- and iso-propyl, n-, iso- and tert-butyl, and the isomers of pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl and dodecyl.
  • R 1 , R 2 and R 3 may contain especially functional groups, such as keto groups, -CN, -NO 2 , carbon double bonds, N-O-, aromatic halogen groups and amide groups.
  • R 1 and R 2 as heteroaryl are preferably a 5- or 6-membered ring having 1 or 2 identical or different hetero atoms, especially O, S or N, which contains preferably 4 or 5 carbon atoms and can be condensed with benzene.
  • heteroaromatics from which R 1 can be derived are furan, pyrrole, thiophene, pyridine, pyrimidine, indole and quinoline.
  • R 1 and R 2 as heteroaryl-substituted alkyl are derived preferably from a 5- or 6-membered ring having 1 or 2 identical or different hetero atoms, especially O, S or N, which contains preferably 4 or 5 carbon atoms and can be condensed with benzene.
  • heteroaromatics are furan, pyrrole, thiophene, pyridine, pyrimidine, indole and quinoline.
  • R 1 and R 2 as heterocycloalkyl or as heterocycloalkyl-substituted alkyl contain preferably from 4 to 6 ring atoms and 1 or 2 identical or different hetero atoms from the group O, S and NR 6 . It can be condensed with benzene. It may be derived, for example, from pyrrolidine, tetrahydrofuran, tetrahydrothiophene, indane, pyrazolidine, oxazolidine, piperidine, piperazine or morpholine.
  • R 1 , R 2 and R 3 as alkyl are preferably unsubstituted or substituted C 1 -C 6 -, especially C 1 -C 4 -alkyl, which may be linear or branched. Examples are methyl, ethyl, iso- and n-propyl, iso-, n- and tert-butyl, the isomers of pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl and dodecyl.
  • R 1 , R 2 and R 3 as unsubstituted or substituted cycloalkyl contain preferably from 3 to 6, especially 5 or 6, ring carbon atoms. Examples are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
  • R 1 , R 2 and R 3 as aryl are preferably unsubstituted or substituted naphthyl and especially phenyl.
  • R 1 , R 2 and R 3 as aralkyl are preferably unsubstituted or substituted phenylalkyl having from 1 to 10, preferably from 1 to 6 and especially from 1 to 4 carbon atoms in the alkylene, the alkylene being linear or branched.
  • Examples are especially benzyl, and 1-phenyleth-1-yl, 2-phenyleth-1-yl, 1-phenylprop-1-yl, 1-phenylprop-2-yl, 1-phenyl- prop-3-yl, 2-phenylprop-1-yl, 2-phenylprop-2-yl and 1-phenylbut-4-yl.
  • R 4 and R 5 are preferably C 1 -C 6 -, especially C 1 -C 4 -alkyl, or R 4 and R 5 together are tetramethylene, pentamethylene or 3-oxapentylene. Examples of alkyl are mentioned hereinbefore.
  • R 1 and R 2 together or R 1 and R 3 together as alkylene are preferably interrupted by 1 -O-, -S- or -NR 6 -, preferably -O-.
  • condensed alkylene R 1 and R 2 together or R 1 and R 3 together are preferably alkylene condensed with benzene or pyridine. Examples of alkylene are: ethylene, 1,2- or
  • condensed alkylene are:
  • R 4 and R 5 are preferably each independently of the other hydrogen, C 1 -C 4 alkyl, phenyl or benzyl.
  • R 6 is preferably hydrogen or C 1 -C 4 alkyl.
  • a further preferred group is formed by prochiral imines in which in formula I R 1 , R 2 and R 3 are each different from the others and are not hydrogen.
  • R 3 is 2,6-di-C 1 -C 4 alkylphen-1-yl and especially 2,6-dimethylphen-1-yl or 2-methyl-6-ethylphen-1-yl
  • R 2 is C 1 -C 4 alkyl and especially ethyl or methyl
  • R 2 is C 1 -C 4 alkyl, C 1 -C 4 alkoxymethyl or C 1 -C 4 alkoxyethyl, and especially methoxymethyl.
  • Imines of formula I are known or they can be prepared in accordance with known processes from aldehydes or ketones and primary amines.
  • the iridium catalysts are preferably homogeneous catalysts that are substantially soluble in the reaction medium.
  • the term "catalyst” also includes catalyst precursors that are converted into an active catalyst species at the beginning of a hydrogenation.
  • the catalysts preferably correspond to the formulae III, IlIa, IIIb, IIIc and Illd,
  • R a and R b are each independently of the other hydrogen, C 1 -C 8 alkyl, C 1 -C 4 fluoroalkyl, phenyl or benzyl or are phenyl or benzyl having from 1 to 3C 1 -C 4 alkyl or C 1 -C 4 alkoxy substituents.
  • R b is preferably hydrogen.
  • R a is preferablyC 1 -C 4 alkyl and especially methyl.
  • the diphosphine Y contains preferably at least one chiral carbon atom and is especially an optically pure stereoisomer (enantiomer or diastereoisomer), or a pair of diastereoisomers, since the use of catalysts containing those ligands leads to optical induction in asymmetric hydrogenation reactions.
  • X as an olefin ligand may be a branched or, preferably, linear C 2 -C 12 alkylene, especially C 2 -C 6 alkylene. Some examples are dodecylene, decylene, octylene, 1-, 2- or 3-hexene, 1-, 2- or 3-pentene, 1- or 2-butene, propene and ethene.
  • X as a diene ligand may be open-chain or cyclic dienes having from 4 to 12, preferably from 5 to 8, carbon atoms, the diene groups preferably being separated by one or two saturated carbon atoms.
  • Some examples are butadiene, pentadiene, hexadiene, heptadiene, octadiene, decadiene, dodecadiene, cyclopentadiene, cyclohexadiene, cycloheptadiene, cyclooctadiene and bridged cyclodienes such as norbornadiene and bicyclo-2,2,2-octadiene. Hexadiene, cyclooctadiene and norbornadiene are preferred.
  • the phosphine groups contain preferably two identical or different, preferably identical, unsubstituted or substituted hydrocarbon radicals having from 1 to 20, especially from 1 to 12 carbon atoms.
  • the secondary phosphine groups contain two identical or different radicals from the following group: linear or branched C 1 -C 12 alkyl; unsubstituted or C 1 -C 6 alkyl- or C 1 -C 6 alkoxy-substituted C 5 -C 12 - cycloalkyl, C 5 -C 12 cycloalkyl-CH 2 -, phenyl or benzyl; and phenyl or benzyl substituted by halogen (e.g.
  • C 1 -C 6 haloalkyl (C 1 -C 12 alkyl) 3 Si, (C 6 H 5 ) 3 Si, C 1 -C 6 haloalkoxy (e.g. trifluoromethoxy), -NH 2 , phenyl 2 N-, benzyl 2 N-, morpholinyl, piperidinyl, pyrrolidinyl, (C 1 -C 12 alkyl) 2 N-, -ammonium-X 1 ⁇ , -SO 3 M 1 , -CO 3 M 1 , -PO 3 M 1 or by -COO-C 1 -C 6 - alkyl (e.g.
  • M 1 is an alkali metal or hydrogen and X 1 ⁇ is the anion of a monobasic acid.
  • M 1 is preferably H, Li, Na or K.
  • A1 ⁇ as the anion of a monobasic acid, is preferably Cl ⁇ , Br ⁇ or the anion of a carboxylic acid, for example formate, acetate, trichloroacetate or trifluoroacetate.
  • a secondary phosphine group may also be a radical of the formula
  • n and n are each independently of the other an integer from 2 to 10, and the sum of m+n is from 4 to 12, especially from 5 to 8. Examples thereof are [3.3.1]- and [4.2.1]-phobyl of the formulae
  • alkyl that preferably contains from 1 to 6 carbon atoms are methyl, ethyl, n-propyl, isopropyl, n-, iso- and tert-butyl and the isomers of pentyl and hexyl.
  • alkyl-substituted cycloalkyl examples include cyclopentyl, cyclohexyl, methyl- or ethyl-cyclohexyl and dimethylcyclohexyl.
  • alkyl-, alkoxy- or haloalkoxysubstituted phenyl and benzyl are methylphenyl, dimethylphenyl, trimethylphenyl, ethylphenyl, methylbenzyl, methoxyphenyl, dimethoxyphenyl, trifluoromethylphenyl, bis-tri-fluoromethylphenyl, tris-trifluoromethylphenyl, trifluoromethoxyphenyl and bis-trifluoromethoxyphenyl.
  • Preferred phosphine groups are those that contain identical or different, preferably identical, radicals from the group C 1 -C 6 alkyl; cyclopentyl and cyclohexyl that are unsubstituted or have from 1 to 3 C 1 -C 4 alkyl or C 1 -C 4 alkoxy substituents, benzyl and, especially, phenyl that is unsubstituted or has from 1 to 3 C 1 -C 4 alkyl, C 1 -C 4 alkoxy, F, Cl,C 1 -C 4 fluoroalkyl or C 1 -C 4 fluoroalkoxy substituents.
  • Y as a diphosphine is preferably of formula IV, IVa, IVb, IVc or IVd,
  • R 7 , R 8 , R 10 and R 11 are each independently of the others a hydrocarbon radical having from 1 to 20 carbon atoms that is unsubstituted or substituted by C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halogen, C 1 -C 6 haloalkyl, (C 1 -C 12 alkyl) 3 Si, (C 6 H 5 ) 3 Si, C 1 -C 6 haloalkoxy, -NH 2 , phenyl 2 N-, benzyl 2 N-, morpholinyl, piperidinyl, pyrrolidinyl, (C 1 -C 12 alkyl) 2 N-, -ammonium-X 1 ⁇ , -SO 3 M 1 , -CO 2 M 1 , -PO 3 M 1 or by -COO-C 1 -C 6 alkyl, wherein Mj is an alkali metal or hydrogen and X 1 is the anion of a monobasic acid
  • R 9 is linear C 2 -C 4 alkylene that is unsubstituted or substituted by C 1 -C 6 alkyl, C5- or C 6 -cycloalkyl, phenyl, naphthyl or by benzyl; 1,2- or 1,3-cycloalkylene or -cycloalkenyl- ene, -bicycloalkylene or -bicycloalkenylene having from 4 to 10 carbon atoms, each of which is unsubstituted or substituted by C 1 -C 6 alkyl, phenyl or by benzyl; 1,2- or
  • R 21 and R 22 are each independently of the other hydrogen, C 1 -C 6 alkyl, phenyl or benzyl; 3,4- or 2,4-pyrrolidinylene or 2-methylene-pyrrolidin-4-yl the nitrogen atom of which is substituted by hydrogen, C 1 -C 12 alkyl, phenyl, benzyl, C 1 -C 12 alkoxycarbonyl, C 1 -C 8 acyl or by C 1 -C 12 alkylaminocarbonyl; or 1,2-phenylene, 2-benzylene, 1,2-xylylene, 1,8-naphthylene, 2,2'-dinaphthylene or 2,2'-diphenylene, each of which is unsubstituted or substituted by C 1 -C 4 alkyl; or R 9 is a radical of the formula
  • R 14 is hydrogen, C 1 -C 8 alkyl, C 1 -C 4 fluoroalkyl, phenyl or phenyl having from 1 to 3 C 1 -C 4 alkyl or C 1 -C 4 alkoxy substituents;
  • R 12 is linear C 2 - or C 3 -alkylene that is unsubstituted or substituted by C 1 -C 6 alkyl, C 5 - or C 6 -cycloalkyl, phenyl, naphthyl or by benzyl; 1,2- or 1,3-cycloalkylene or -cycloalkenylene, -bicycloalkylene or -bicycloalkenylene having from 4 to 10 carbon atoms, each of which is unsubstituted or substituted by C 1 -C 6 alkyl, phenyl or by benzyl; or 1,2- or 1,3- cycloalkylene or -cycloalkenylene, -bicycloalkylene or -bicycloalkenylene having from 4 to 10 carbon atoms, each of which is unsubstituted or substituted by C 1 -C 6 alkyl, phenyl or by benzyl, and in the 1- and/or 2-positions or in the 3-
  • R 13 is linear C 2 alkylene that is unsubstituted or substituted by C 1 -C 6 alkyl, C 5 - or
  • R c is hydrogen, C 1 -C 4 alkyl, phenyl or benzyl.
  • R 7 , R 8 , R 10 and R 11 are preferably identical or different, preferably identical, radicals from the following group: C 1 -C 6 alkyl; cyclopentyl and cyclohexyl that are unsubstituted or have from 1 to 3 C 1 -C 4 alkyl or C 1 -C 4 alkoxy substituents, benzyl and, especially, phenyl that is unsubstituted or has from 1 to 3 C 1 -C 4 alkyl, C 1 -C 4 alkoxy, F, Cl, C 1 -C 4 fluoroalkyl or C 1 -C 4 fluoroalkoxy substituents.
  • a preferred subgroup of diphosphines Y is formed by those of the formulae
  • R 15 and R 16 are each independently of the other hydrogen, C 1 -C 4 alkyl, phenyl, benzyl, or phenyl or benzyl having from 1 to 3 C 1 -C 4 alkyl or C 1 -C 4 alkoxy substituents,
  • R 14 is hydrogen, C 1 -C 4 alkyl, phenyl, benzyl, or phenyl or benzyl having from 1 to 3
  • R 17 is hydrogen, C 1 -C 4 alkyl, phenyl, benzyl, C 1 -C 6 alkoxy-CO-, C 1 -C 6 alkyl-CO-, phenyl-CO-, naphthyl-CO- or C 1 -C 4 alkylNH-CO-,
  • A may be identical or different groups -PR 2 , wherein R is C 1 -C 6 alkyl, cyclohexyl, phenyl, benzyl, or phenyl or benzyl having from 1 to 3 C 1 -C 4 alkyl, C 1 -C 4 alkoxy, -CF 3 or partially or fully fluorinated C 1 -C 4 alkoxy substituents, and
  • n 0, 1 or 2.
  • diphosphines Y are as follows (Ph is phenyl):
  • A® in formula ⁇ la can be derived from inorganic or organic oxy acids. Examples of such acids are H 2 SO 4 , HClO 4 , HCIO 3 , HBrO 4 , HIO 4 , HNO 3 , H 3 PO 3 , H 3 PO 4 , CF 3 SO 3 H, C 6 H 5 SO 3 H, CF 3 COOH and CCl 3 COOH.
  • Complex acids from which A® can be derived are, for example, the halo complex acids of the elements B, P, As, Sb and Bi.
  • a ⁇ in formula Ilia are ClO 4 ⁇ , C F3 SO 3 ⁇ , BF 4 ⁇ , B(phenyl) 4 ⁇ , PF 6 ⁇ , SbCl 6 ⁇ , AsF 6 ⁇ and SbF 6 ⁇ .
  • M ⁇ in formula mb is an alkali metal cation, it may be, for example, a Li, Na, K, Rb or Cs cation.
  • M ⁇ is quaternary ammonium, it may contain a total of from 4 to 40, preferably from 4 to 24, carbon atoms.
  • M ⁇ may correspond to the formula phenyl- N ⁇ (C 1 -C 6 alkyl) 3 , benzylN ⁇ (C 1 -C 6 alkyl) 3 or (C 1 -C 6 alkyl) 4 N ⁇ .
  • M ⁇ in formula IIIb is preferably Li ⁇ , Na ⁇ or K ⁇ or (C 1 -C 6 alkyl) 4 N ⁇ .
  • Z in formula III is preferably Br or Cl and especially Cl.
  • Z in formula lIb is preferably Br or I and Z in formulae IIIe and IIId is preferably I.
  • diphosphine ligands which can preferably be used in catalysts of formula (III) are, for example:
  • the preparation of the catalysts of formula HI can be carried out, for example, by reacting a diiridium complex of the formula [IrXZ] 2 with a diphosphine Y.
  • the iridium catalysts can be added to the reaction mixture as isolated compounds. It has proved advantageous, however, to produce the catalyst in situ with or without a solvent prior to the reaction and to add optionally a portion or all of the acid and of an ammonium or alkali metal halide.
  • the iridium catalysts are preferably used in amounts of from 0.0001 to 10 mol %, especially from 0.001 to 10 mol %, and more especially from 0.01 to 5 mol %, based on the imine.
  • the molar ratio of the imine to the iridium catalyst may be, for example, from 5000000 to 10, especially from 2000000 to 20, more preferably from 1 000000 to 20, and more especially from 500000 to 100.
  • the process is carried out preferably at a temperature of from -20 to 100°C, especially from 0 to 80°C and more especially from 10 to 70°C, and preferably at a hydrogen pressure of 2 ⁇ 10 5 to 1.5 ⁇ 10 7 Pa (5 to 150 bar), especially 10 6 to 10 7 Pa (10 to 100 bar).
  • the chorides, bromides and iodides employed are preferably used in concentrations of from 0.01 to 500 mmol/1, especially from 0.01 to 50 mmol/1, based on the volume of the reaction mixture.
  • the process according to the invention comprises the additional concomitant use of an ammonium or metal chloride, bromide or iodide.
  • the chlorides, bromides and iodides are used preferably in amounts of from 0.01 to 200 mol %, especially from 0.05 to 100 mol % and more especially from 0.5 to 50 mol %, based on the iridium catalyst.
  • the iodides are preferred.
  • Ammonium is preferably tetraalkylammonium having from 1 to 6 carbon atoms in the alkyl groups, and the metal is preferably sodium, lithium or potassium. Special preference is given to tetrabutylammonium iodide and sodium.
  • Suitable solvents which can be used alone or as a mixture of solvents, are especially aprotic solvents.
  • aliphatic and aromatic hydrocarbons such as pentane, hexane, cyclohexane, methylcyclohexane, benzene, toluene and xylene
  • ethers such as diethyl ether, diethylene glycol dimethyl ether, tetrahydrofuran and dioxane
  • halogenated hydrocarbons such as methylene chloride, chloroform, 1,1,2,2-tetrachloroethane and chlorobenzene
  • esters and lactones such as ethyl acetate, butyrolactone and valerolactone
  • acid amides and lactams such as dimethylformamide, dimethylacetamide and N-methylpyrrolidone, and ketones, such as acetone, dibutanediol, 1,1,2,2-tetrachloroethan
  • the process according to the invention further comprises the additional concomitant use of an acid.
  • an acid may be an inorganic or, preferably, an organic acid.
  • the acid is preferably used in at least the same molar amount as the iridium catalyst (equivalent to catalytic amounts) and can also be used in excess. The excess may even consist in the use of the acid as solvent.
  • Preferably from 0.001 to 50, in particular from 0.1 to 50 % by weight of acid is used, based on the amine. In many cases it can be advantageous to use anhydrous acids.
  • inorganic acids are H 2 SO 4 , highly concentrated sulfuric acid (oleum), H 3 PO 4 , orthophosphoric acid, HF, HCl, HBr, HI, HClO 4 , HBF 4 , HPF 6 , HAsF 6 , HSbCl 6 , HSbF 6 and HB(phenyl) 4 .
  • H 2 SO 4 is particularly preferred.
  • organic acids are aliphatic or aromatic, optionally halogenated (fluorinated or chlorinated) carboxylic acids, sulfonic acids, phosphorus(V) acids (for example phosphonic acids, phosphonous acids) having preferably from 1 to 20, especially from 1 to 12 and more especially from 1 to 6, carbon atoms.
  • Examples are formic acid, acetic acid, propionic acid, butyric acid, benzoic acid, phenylacetic acid, cyclohexanecarboxylic acid, chloroor fluoro-acetic acid, dichloro- or difluoro-acetic acid, trichloro- or trifluoro-acetic acid, chlorobenzoic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, chlorobenzenesulfomc acid, trifluoromethanesulfonic acid, methylphosphonic acid and phenylphosphonic acid.
  • Preferred acids are acetic acid, propionic acid, trifluoroacetic acid, methanesulfonic acid and chloroacetic acid.
  • the process according to the invention can be carried out by first preparing the catalyst by dissolving, for example, (Ir-dieneCl) 2 in a solvent or an acid or both, adding a diphosphine and then an alkali metal or ammonium halide and stirring the mixture.
  • (Ir-dieneCl) 2 can also be used in solid form.
  • a solution of imines is added to that catalyst solution (or vice versa) and, in an autoclave, hydrogen pressure is applied, thus removing the protective gas that is advantageously used. It is advantageous to ensure that the catalyst solution stands for only a short time, and to carry out the hydrogenation of the imines as soon as possible after the preparation of the catalyst.
  • the reaction mixture is heated, if desired, and then hydrogenated. Where appropriate, when the reaction has ceased the reaction mixture is cooled and the autoclave is depressurised.
  • the reaction mixture can be removed from the autoclave under pressure with nitrogen and the hydrogenated organic compound can be isolated and purified in a manner known per se, for example by precipitation, extraction or distillation.
  • the aldimines and ketimines can also be formed in situ before or during the hydrogenation.
  • an amine and an aldehyde or a ketone are mixed together and added to the catalyst solution and the aldimine or ketimine formed in situ is hydrogenated. It is also possible, however, to use an amine, a ketone or an aldehyde together with the catalyst as the initial batch and to add the ketone or the aldehyde or the amine thereto, either all at once or in metered amounts.
  • the hydrogenation can be carried out continuously or batchwise in various types of reactor. Preference is given to those reactors which allow comparatively good intermixing and good removal of heat, such as, for example, loop reactors. That type of reactor has proved to be especially satisfactory when small amounts of catalyst are used.
  • the process according to the invention yields the corresponding amines in short reaction times while having chemically a high degree of conversion, with surprisingly good optical yields (ee) of 70 % or more being obtained even at relatively high temperatures of more than 50°C, and even with high molar ratios of imine to catalyst.
  • the hydrogenated organic compounds that can be prepared in accordance with the invention are biologically active substances or are intermediates for the preparation of such substances, especially in the field of the preparation of pharma ceuticals and agrochemicals.
  • o,o-dialkylarylketamine derivatives especially those having alkyl and/or alkoxyalkyl groups, are effective as fungicides, especially as herbicides.
  • the derivatives may be amine salts, acid amides, for example of chloroacetic acid, tertiary amines and ammonium salts (see, for example, EP-A-0077755 and EP-A-0 115 470).
  • optically active amines of formula 1 Especially important in this connection are the optically active amines of formula
  • R 01 , R 02 and R 03 are each independently of the others C 1 -C 4 alkyl, and R 04 is C 1 -C 4 alkyl or C 1 -C 4 alkoxymethyl or C 1 -C 4 alkoxyethyl, and especially the amines of the formulae
  • Example 1 Preparation of N-(2'-methyl-6'-ethyl-phen-1'-yl)-N-(1-methoxymethyl)ethyl amine.
  • the hydrogen is depressurised and the reaction solution is expelled under pressure from the autoclave.
  • the conversion is 100 %.
  • 100 ml of toluene are added and then toluene and acetic acid are removed in a rotary evaporator.
  • the residue is distilled under a high vacuum (0.1 mbar), yielding 401 g (yield of 97 %) of pure
  • the methoxyacetone solution and the catalyst solution are transferred in succession to a 50 ml steel autoclave which is under an inert gas. In four cycles (10 bar, normal pressure) the inert gas is displaced by hydrogen. Then a pressure of 40 bar of hydrogen is applied and the autoclave is heated to 50°C. After a reaction time of 18 hours, the reaction is discontinued and the reaction solution is cooled to room temperature. Working up is effected in accordance with Example 1. The conversion is 97 % (based on 2-methyl-6-ethylaniline) and the optical yield is 75.6 % (S).
  • That solution is transferred by means of a steel capillary to a 50 ml steel autoclave which is under argon. Then a pressure of 30 bar of hydrogen is applied as described in Example 1 and then the reaction solution is sti ⁇ ed for 20 minutes at room temperature. The reaction is discontinued, the hydrogen is depressurised and the reaction solution is expelled under pressure from the autoclave. Conversion is 100 %.
  • the solvent (toluene) and acid additive (acetic acid) are removed in a rotary evaporator, yielding 1.2 g of oily crude product, which is then purified by flash chromatography (silica gel 0.040 - 0.063 mm, eluant hexane/ethyl acetate (3:1)). The enantiomeric purity of the isolated product is 76.1%.
  • Example 10 the process is carried out analogously to Example 6, but with the following modified reaction conditions: 105 g (0.5 mol) of N-(2'-methyl-6'-ethyl-phen- 1'-yl)-N-(1-methoxymethyl)ethylideneamine, 1.7 mg (0.0025 mmol) of [Ir(1,5-cyclooctadiene)Cl] 2 , 3.8 mg (0.0059 mmol) of ⁇ (R)-1-[(S)-2-diphenylphosphino)ferrocenyl] ⁇ ethyldi(3,5-dimethylphenyl)phosphine, 70 mg (0.189 mmol) of tetrabutylammonium iodide, 80 bar of hydrogen and 50°C.
  • Table 1 The acids used and the results of the respective tests are shown in Table 1.
  • Example 34 Preparation of N-(2',6'-dimemylphen-1'-yl)-N-(1-methoxymethyl)ethylamine
  • the process is carried out as in Example 6 but the reaction conditions are modified as follows: 514 g (2.6 mol) of N-(2',6 , -dimethylphen-1'-yl)-N-(1-memoxymethyl)ethylamine, 77 mg (0.115 mmol) of [Ir(1,5-cyclooctadiene)Cl] 2 , 214 mg (0.27 mmol) of ⁇ (R)-1-[(S)-2-diphenylphosphino)ferrocenyl] ⁇ ethyl-di(3,5-dimethyl-4-N,N-dipropylaminophenyl)phosphine, 3.5 g (9.5 mmol) of tetrabutylammonium iodide, 50 ml of acetic
  • Example 35 Preparation of N-(2',6'-dimethylphen-1'-yl)-N-(1-methoxymethyl)ethylamine The process is carried out as in Example 33 but the reaction conditions are modified as follows:
  • the reaction mixture is poured onto 20 litres of water and the resulting emulsion is stirred vigorously for 10 minutes.
  • the aqueous phase is extracted once with 10 litres of hexane.
  • the combined organic phases are washed once with 10 litres of water, once with 5 litres of 2N hydrochloric acid and once with 10 litres of water, dried over sodium sulfate and filtered, and concentrated in a rotary evaporator.
  • the crude product so obtained is subjected to fractional distillation. B.p. 0.1 135-140°C; ee 81.0 %;
  • Example 6 The process is carried out as in Example 6, but the reaction conditions are modified as follows: in a 11-reaction vessel 413 g (2,004 mmol) of the imine, 2,8 mg of the iridium compound, 6,4 mg of the diphosphine ligand and 124,2 mg of the iodide are used. Instead of 2 ml of acetic acid 0, 1 g of H 2 SO 4 are used.
  • the conversion is 100 %. After isolation and purification according to Example 6 one obtains 99 % of the desired product, the optical yield being 76,0 %(S).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Catalysts (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
PCT/EP1995/000221 1994-02-02 1995-01-21 Process for the hydrogenation of imines Ceased WO1995021151A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP52034895A JP3833699B2 (ja) 1994-02-02 1995-01-21 イミンの水素化法
EP95906339A EP0691949B1 (en) 1994-02-02 1995-01-21 Process for the hydrogenation of imines
CA002157191A CA2157191C (en) 1994-02-02 1995-01-21 Process for the hydrogenation of imines
SK1366-95A SK281759B6 (sk) 1994-02-02 1995-01-21 Spôsob hydrogenácie imínov
HU9502851A HU219731B (hu) 1994-02-02 1995-01-21 Eljárás iminek hidrogénezésére
KR1019950704200A KR100355255B1 (ko) 1994-02-02 1995-01-21 이민의수소화방법
DE69505312T DE69505312T2 (de) 1994-02-02 1995-01-21 Verfahren zur hydrierung von iminen
PL95310965A PL179441B1 (pl) 1994-02-02 1995-01-21 Sposób uwodorniania co najmniej jednej grupy C=N- zawartej w iminie PL PL
AU14566/95A AU677753B2 (en) 1994-02-02 1995-01-21 Process for the hydrogenation of imines
BR9505836A BR9505836A (pt) 1994-02-02 1995-01-21 Processo para a hidrogenaçao de iminas
DK95906339T DK0691949T3 (da) 1994-02-02 1995-01-21 Fremgangsmåde til hydrogenering af iminer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH309/94-0 1994-02-02
CH30994 1994-02-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US08/926,835 Continuation US6822118B1 (en) 1994-02-02 1997-09-10 Process for the hydrogenation of imines

Publications (1)

Publication Number Publication Date
WO1995021151A1 true WO1995021151A1 (en) 1995-08-10

Family

ID=4184068

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/000221 Ceased WO1995021151A1 (en) 1994-02-02 1995-01-21 Process for the hydrogenation of imines

Country Status (21)

Country Link
US (1) US6822118B1 (enExample)
EP (1) EP0691949B1 (enExample)
JP (1) JP3833699B2 (enExample)
KR (1) KR100355255B1 (enExample)
CN (1) CN1117727C (enExample)
AT (1) ATE172184T1 (enExample)
AU (1) AU677753B2 (enExample)
BR (1) BR9505836A (enExample)
CZ (1) CZ287162B6 (enExample)
DE (1) DE69505312T2 (enExample)
DK (1) DK0691949T3 (enExample)
ES (1) ES2123953T3 (enExample)
HR (1) HRP950046B1 (enExample)
HU (1) HU219731B (enExample)
IL (1) IL112492A (enExample)
PL (1) PL179441B1 (enExample)
RU (1) RU2150464C1 (enExample)
SK (1) SK281759B6 (enExample)
TW (1) TW272141B (enExample)
WO (1) WO1995021151A1 (enExample)
ZA (1) ZA95781B (enExample)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000375A1 (fr) * 1996-06-28 1998-01-08 Rhodia Chimie Procede d'hydrogenation asymetrique d'un compose cetonique et derive
US6017918A (en) * 1998-08-06 2000-01-25 Warner-Lambert Company Phenyl glycine compounds and methods of treating atherosclerosis and restenosis
EP1078915A1 (en) * 1999-08-27 2001-02-28 Johnson Matthey Public Limited Company Reductive amination process using a homogeneous iridium catalyst
US6284795B1 (en) 1998-09-04 2001-09-04 Warner-Lambert Company Sulfonamide compounds and methods of treating atherosclerosis and restenosis
RU2198161C2 (ru) * 1996-11-05 2003-02-10 Байер Аг Способ получения 2-метил-2,4-диаминопентана
WO2005095426A1 (en) * 2004-03-12 2005-10-13 Degussa Ag Process for preparing enantiomerically enriched ferrocenyl ligands
WO2006082054A1 (en) * 2005-02-04 2006-08-10 Universita' Degli Studi Di Milano 1,4-bis-diphosphines, 1,4-bis-diphosphites and 1,4-bis- diphosphonites from optically active (z)-olefines as chiral ligands
EP2363388A1 (en) * 2010-03-02 2011-09-07 DSM IP Assets B.V. Process for the production of chiral amines
EP1202952B2 (de) 1999-07-17 2014-07-09 Evonik Degussa GmbH Verfahren zur herstellung von aminen durch homogen katalysierte reduktive aminierung von carbonylverbindungen
US8791300B2 (en) 2005-11-02 2014-07-29 Gruenenthal Gmbh Process for preparing a substituted dimethyl-(3-arylbutyl)amine compound by homogeneous catalysis
WO2016153374A1 (en) 2015-03-20 2016-09-29 Sapec Agro S.A. Process of production of (s) -metolachlor
CN109422602A (zh) * 2017-08-29 2019-03-05 中国科学院大连化学物理研究所 一种不对称氢化亚胺制备手性胺的方法
WO2021013997A1 (en) * 2019-07-25 2021-01-28 Medichem, S.A. Process for the synthesis of n-alkyl-4-pyridinamines
WO2024052910A1 (en) * 2022-09-07 2024-03-14 Adama Agan Ltd. Process for the preparation of dimethenamid

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE522539T1 (de) * 2003-07-22 2011-09-15 Idemitsu Kosan Co Iridiumorganischer komplex und elektrolumineszenzgerät, in dem dieser verwendet wird
US7803952B2 (en) 2005-04-08 2010-09-28 Dsm Ip Assets B.V. Manufacture of lactones
ES2409206T3 (es) 2005-04-15 2013-06-25 Dsm Ip Assets B.V. Fabricación de tiolactonas
WO2006111535A2 (en) * 2005-04-20 2006-10-26 Umicore Ag & Co. Kg Diphosphines and metal complexes
US20070213540A1 (en) * 2006-03-09 2007-09-13 Degussa Ag Process for the hydrogenation of imines
BRPI0907343A8 (pt) * 2008-04-17 2017-05-23 United Phosphorus Ltd Hidrogenação de iminas
MX2010014510A (es) * 2008-06-27 2011-02-22 Merck Frosst Canada Ltd Sintesis de aminas quirales.
RU2371919C1 (ru) * 2008-08-06 2009-11-10 Закрытое акционерное общество "АЛЬФА-ТЭК" Способ борьбы с грибковыми и бактериальными заболеваниями сельскохозяйственных растений
EP2202236A1 (en) 2008-12-23 2010-06-30 Solvias AG Chiral ligands
CN101857612B (zh) * 2010-06-11 2016-03-23 南京工业大学 一类手性双膦配体及其铱复合催化剂、制备方法及在不对称氢化合成(s)-异丙甲草胺中的应用
CN102951980A (zh) * 2011-08-23 2013-03-06 中国中化股份有限公司 一种亚胺不对称催化加氢的方法
CN102950025B (zh) * 2011-08-23 2014-09-10 中国中化股份有限公司 一种亚胺不对称加氢催化剂及其用途
WO2014037962A1 (en) 2012-09-06 2014-03-13 Council Of Scientific And Industrial Research Process for the preparation of (s)-2-ethyl-n-(1-methoxypropan -2-yl)-6-methyl aniline
CN104557563B (zh) * 2013-10-22 2017-04-26 中国石油化工股份有限公司 一种合成(r)‑1‑苯基丁胺的方法
GB202216812D0 (en) 2022-11-10 2022-12-28 Univ Court Univ St Andrews Process

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256982A2 (de) * 1986-08-04 1988-02-24 Ciba-Geigy Ag Verfahren zur Herstellung von optisch aktiven sekundären Arylaminen
EP0301457A2 (de) * 1987-07-28 1989-02-01 Ciba-Geigy Ag Verfahren zur Herstellung von optisch aktiven sekundären Aminen
WO1992015400A1 (en) * 1991-03-06 1992-09-17 Monsanto Company Ruthenium-binap asymmetric hydrogenation catalyst
EP0564406A1 (de) * 1992-04-02 1993-10-06 Ciba-Geigy Ag Ferrocenyldiphosphine als Liganden für homogene Katalysatoren

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2825543A1 (de) * 1978-06-10 1979-12-13 Bayer Ag N-substituierte halogenacetanilide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
EP0077755B1 (de) * 1981-10-16 1985-03-06 Ciba-Geigy Ag Optisch aktives N-(1'-Methyl-2'-methoxyäthyl)-N-chloracetyl-2-äthyl-6-methylanilin als Herbizid
EP0115470B1 (de) * 1983-01-25 1986-12-17 Ciba-Geigy Ag Optisch aktives N-(1'-Methyl-2'-methoxyethyl)-N-chloracetyl-2,6-di-methylanilin als Herbizid
FR2550201B1 (fr) * 1983-08-05 1986-02-28 Charbonnages Ste Chimique Ligands phosphores chiraux, leur procede de fabrication a partir d'aminoacides naturels et leur application a la catalyse de reactions de synthese enantioselective
US4705877A (en) * 1987-02-25 1987-11-10 Dow Corning Corporation Novel aminohydrocarbyl-substituted ketoximosilanes
EP0384086A1 (en) * 1989-02-10 1990-08-29 BP Chimie Société Anonyme Synthesis of hydrocarbyl amines
US5112999A (en) 1989-09-18 1992-05-12 Ciba-Geigy Corporation Iridium complexes, process for their preparation and their use
US5250731A (en) * 1992-03-17 1993-10-05 E. I. Du Pont De Nemours And Company Preparation of optically active hydrazines and amines
UA51652C2 (uk) * 1995-06-08 2002-12-16 Новартіс Аг Спосіб гідрування імінів
HRP960302A2 (en) * 1995-07-26 1998-04-30 Ciba Geigy Ag Process for the hydrogenation of imines

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256982A2 (de) * 1986-08-04 1988-02-24 Ciba-Geigy Ag Verfahren zur Herstellung von optisch aktiven sekundären Arylaminen
US4994615A (en) * 1986-08-04 1991-02-19 Ciba-Geigy Corporation Process for the preparation of optically active secondary arylamines
EP0301457A2 (de) * 1987-07-28 1989-02-01 Ciba-Geigy Ag Verfahren zur Herstellung von optisch aktiven sekundären Aminen
US5011995A (en) * 1987-07-28 1991-04-30 Ciba-Geigy Corporation Process for the preparation of optically active secondary amines
WO1992015400A1 (en) * 1991-03-06 1992-09-17 Monsanto Company Ruthenium-binap asymmetric hydrogenation catalyst
EP0564406A1 (de) * 1992-04-02 1993-10-06 Ciba-Geigy Ag Ferrocenyldiphosphine als Liganden für homogene Katalysatoren

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166257A (en) * 1996-06-28 2000-12-26 Rhodia Chimie Asymmetric hydrogenation method of a ketonic compound and derivative
WO1998000375A1 (fr) * 1996-06-28 1998-01-08 Rhodia Chimie Procede d'hydrogenation asymetrique d'un compose cetonique et derive
RU2198161C2 (ru) * 1996-11-05 2003-02-10 Байер Аг Способ получения 2-метил-2,4-диаминопентана
US6017918A (en) * 1998-08-06 2000-01-25 Warner-Lambert Company Phenyl glycine compounds and methods of treating atherosclerosis and restenosis
US6284795B1 (en) 1998-09-04 2001-09-04 Warner-Lambert Company Sulfonamide compounds and methods of treating atherosclerosis and restenosis
US6458815B2 (en) 1998-09-04 2002-10-01 Warner-Lambert Company Sulfonamide compounds and methods of treating atherosclerosis and restenosis
EP1202952B2 (de) 1999-07-17 2014-07-09 Evonik Degussa GmbH Verfahren zur herstellung von aminen durch homogen katalysierte reduktive aminierung von carbonylverbindungen
EP1078915A1 (en) * 1999-08-27 2001-02-28 Johnson Matthey Public Limited Company Reductive amination process using a homogeneous iridium catalyst
US6323370B1 (en) 1999-08-27 2001-11-27 Johnson Matthey Public Limited Company Catalytic process
WO2005095426A1 (en) * 2004-03-12 2005-10-13 Degussa Ag Process for preparing enantiomerically enriched ferrocenyl ligands
WO2006082054A1 (en) * 2005-02-04 2006-08-10 Universita' Degli Studi Di Milano 1,4-bis-diphosphines, 1,4-bis-diphosphites and 1,4-bis- diphosphonites from optically active (z)-olefines as chiral ligands
US8791300B2 (en) 2005-11-02 2014-07-29 Gruenenthal Gmbh Process for preparing a substituted dimethyl-(3-arylbutyl)amine compound by homogeneous catalysis
EP2363388A1 (en) * 2010-03-02 2011-09-07 DSM IP Assets B.V. Process for the production of chiral amines
WO2016153374A1 (en) 2015-03-20 2016-09-29 Sapec Agro S.A. Process of production of (s) -metolachlor
CN109422602A (zh) * 2017-08-29 2019-03-05 中国科学院大连化学物理研究所 一种不对称氢化亚胺制备手性胺的方法
WO2021013997A1 (en) * 2019-07-25 2021-01-28 Medichem, S.A. Process for the synthesis of n-alkyl-4-pyridinamines
WO2024052910A1 (en) * 2022-09-07 2024-03-14 Adama Agan Ltd. Process for the preparation of dimethenamid

Also Published As

Publication number Publication date
DE69505312D1 (de) 1998-11-19
IL112492A0 (en) 1995-03-30
IL112492A (en) 1999-12-31
EP0691949B1 (en) 1998-10-14
SK136695A3 (en) 1996-02-07
RU2150464C1 (ru) 2000-06-10
JP3833699B2 (ja) 2006-10-18
SK281759B6 (sk) 2001-07-10
AU677753B2 (en) 1997-05-01
CZ287162B6 (en) 2000-10-11
ATE172184T1 (de) 1998-10-15
KR960700995A (ko) 1996-02-24
CN1123024A (zh) 1996-05-22
DK0691949T3 (da) 1999-06-23
HUT75955A (en) 1997-05-28
HRP950046A2 (en) 1997-06-30
JPH08508753A (ja) 1996-09-17
PL179441B1 (pl) 2000-09-29
BR9505836A (pt) 1996-02-27
AU1456695A (en) 1995-08-21
ZA95781B (en) 1995-08-02
US6822118B1 (en) 2004-11-23
HU9502851D0 (en) 1995-12-28
HU219731B (hu) 2001-07-30
ES2123953T3 (es) 1999-01-16
PL310965A1 (en) 1996-01-22
EP0691949A1 (en) 1996-01-17
DE69505312T2 (de) 1999-04-08
CZ285695A3 (en) 1996-03-13
CN1117727C (zh) 2003-08-13
KR100355255B1 (ko) 2002-12-31
TW272141B (enExample) 1996-03-11
HRP950046B1 (en) 2000-12-31

Similar Documents

Publication Publication Date Title
EP0691949B1 (en) Process for the hydrogenation of imines
EP0830337B1 (en) Process for the hydrogenation of imines
US20090036713A1 (en) Process for the hydrogenation of imines
EP0741738B1 (en) Hydrogenation catalyst, process for the preparation thereof and hydrogenation process
WO2010094164A1 (en) Process for the hydrogenation of imines
EP0850241B1 (en) Iridium-diphosphine complexes and process for the hydrogenation of imines
EP0848697B1 (en) Process for the hydrogenation of imines
CA2157191C (en) Process for the hydrogenation of imines
EP0842140B1 (en) Process for the hydrogenation of imines
CA2181366C (en) Hydrogenation catalyst, process for the preparation thereof and hydrogenation process

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95190058.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KG KP KR KZ LK LR LT LV MD MG MN MX NO NZ PL RO RU SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1995906339

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2157191

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 1995 532779

Country of ref document: US

Date of ref document: 19950929

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019950704200

Country of ref document: KR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 136695

Country of ref document: SK

Ref document number: PV1995-2856

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1995906339

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1995-2856

Country of ref document: CZ

EX32 Extension under rule 32 effected after completion of technical preparation for international publication

Free format text: TM

ENP Entry into the national phase

Ref document number: 1997 926835

Country of ref document: US

Date of ref document: 19970910

Kind code of ref document: A

WWG Wipo information: grant in national office

Ref document number: 1995906339

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: PV1995-2856

Country of ref document: CZ